Southern Jo, Waight Pauline A, Andrews Nick, Miller Elizabeth
Immunisation Department, National Infection Service, Public Health England, 61 Colindale Ave, London NW9 5EQ, United Kingdom.
Immunisation Department, National Infection Service, Public Health England, 61 Colindale Ave, London NW9 5EQ, United Kingdom.
Vaccine. 2017 Jan 23;35(4):619-625. doi: 10.1016/j.vaccine.2016.12.017. Epub 2016 Dec 23.
Extensive limb swelling (ESL) after a booster dose of acellular pertussis (aP) containing vaccine can cause concern and has the potential to be confused with cellulitis. In the United Kingdom aP-containing vaccine was introduced for primary immunisation at 2, 3 and 4months of age in 2004, with the first cohorts eligible to receive a fourth dose in 2007 at school entry. We assessed the frequency of ESL (here defined as swelling >100mms diameter) in 973 children receiving a fourth dose of one of four aP vaccines given combined with inactivated polio, tetanus and either low dose diphtheria (TdaP/IPV) or high dose diphtheria (DTaP/IPV) vaccine; 2 of the 3 DTaP/IPV vaccines also contained Haemophilus influenza b conjugate vaccine (Hib). Post-vaccination symptoms and local reactions were recorded in 7-day diaries or by a telephone follow up if no diary was returned. Local swellings >50mm diameter were reported by 2.2% TdaP/IPV recipients compared with 6.6-11.1% of DTaP/IPV recipients; the corresponding proportions for redness >50mms was 7.0% for TdaP/IPV and 13.3-17.7% for DTaP/IPV recipients. Among the latter, the addition of Hib did not affect the frequency or size of local reactions. Pain at the injection site and systemic symptoms did not differ between the four vaccine groups. A history of atopy was not associated with development of local swelling or redness. A total of 13 children (1.3%) experienced an ESL, three after TdaP/IPV. ESLs resolved without systemic upset within a few days and were usually painless; medical advice was only sought for two children. Parents should be informed about the possible occurrence of an ESL with the pre-school aP-containing booster vaccine but can be reassured that it is a benign and transient condition.
接种含无细胞百日咳(aP)疫苗加强针后出现的广泛性肢体肿胀(ESL)可能会引起关注,并且有可能与蜂窝织炎相混淆。在英国,2004年开始在2、3和4月龄时将含aP疫苗用于初次免疫,首批符合条件的儿童于2007年入学时接种第四剂。我们评估了973名接种第四剂四种aP疫苗之一(与灭活脊髓灰质炎、破伤风以及低剂量白喉(TdaP/IPV)或高剂量白喉(DTaP/IPV)疫苗联合使用)的儿童中ESL(此处定义为直径>100mm的肿胀)的发生频率;3种DTaP/IPV疫苗中有2种还含有b型流感嗜血杆菌结合疫苗(Hib)。接种疫苗后的症状和局部反应通过7天日记记录,若未返回日记则通过电话随访记录。TdaP/IPV接种者中报告直径>50mm局部肿胀的比例为2.2%,而DTaP/IPV接种者中这一比例为6.6%-11.1%;TdaP/IPV接种者中发红>50mm的相应比例为7.0%,DTaP/IPV接种者中为13.3%-17.7%。在后者中,添加Hib并不影响局部反应的频率或大小。四个疫苗组之间注射部位疼痛和全身症状无差异。特应性病史与局部肿胀或发红的发生无关。共有13名儿童(1.3%)出现ESL,3名在接种TdaP/IPV后出现。ESL在几天内自行消退,无全身不适,通常无痛;仅两名儿童寻求了医疗建议。应告知家长,学龄前含aP加强疫苗可能会出现ESL,但可以放心的是,这是一种良性且短暂的情况。